Monroe County Medical Society Community-wide Guidelines

Prevention, Diagnosis and Management of Coronary Artery Disease

**Purpose**
To identify and promote the essential elements to preventing, diagnosing, and managing coronary artery disease in adults.

**Key Recommendations**
- Conduct aggressive risk factor management for coronary artery disease beginning at age 20.
- Advise patients about importance of lifestyle as the foundation for risk reduction prior to and during cholesterol-lowering therapy: heart healthy diet; maintenance of a healthy weight; regular aerobic physical activity; avoidance of tobacco products (including electronic nicotine delivery systems [ENDS]/cessation of tobacco use and reducing exposure to second-hand smoke).
- Initiate beta-blockers, ACE inhibitors, and antplatelet agents. ACE inhibitors and antplatelet agents should be considered for indefinite use if no contraindication. The duration of therapy with beta-blockers must be weighed against potential for adverse effects associated with these agents including heart failure and cardiogenic shock.
- ASA Therapy:
  1) **Primary Prevention** – The Food and Drug Administration does not recommend aspirin therapy as preventive medicine in people who have not already had a heart attack, stroke or other cardiovascular conditions. As of 2015, the United States Preventive Services Task Force updated its 2009 recommendation for Aspirin for the Prevention of Cardiovascular Disease – Primary Prevention:

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men, Age 45-79</td>
<td>The USPSTF recommends the use of aspirin for men age 45 to 79 years when the potential benefit due to a reduction in myocardial infarctions outweighs the potential harm due to an increase in gastrointestinal hemorrhage. See the Clinical Considerations section for discussion of benefits and harms.</td>
</tr>
<tr>
<td>Women, Age 55-79</td>
<td>The USPSTF recommends the use of aspirin for women age 55 to 79 years when the potential benefit of a reduction in ischemic strokes outweighs the potential harm of an increase in gastrointestinal hemorrhage. See the Clinical Considerations section for discussion of benefits and harms.</td>
</tr>
<tr>
<td>Men and Women, 80 Years and Older</td>
<td>The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of aspirin for cardiovascular disease prevention in men and women 80 years or older. See the Clinical Considerations section for suggestions for practice regarding the I statement.</td>
</tr>
<tr>
<td>Women Younger than 55 (Stroke), Men Younger than 45 (MI)</td>
<td>The USPSTF recommends against the use of aspirin for stroke prevention in women younger than 55 years and for myocardial infarction prevention in men younger than 45 years.</td>
</tr>
</tbody>
</table>

2) **Secondary Prevention** – 2 or more risk factors, especially those with CHD 10 yr risk of ≥ 10%, and no contraindications, prescribe 81-162 mg/QD.

- Monitor blood pressure. Treat to blood pressure target levels: < 140/90 mm Hg for ages < 60 and < 150/90 mm Hg for ages ≥ 60 with no diabetes and no kidney disease.a, b

  **NOTE:** The recently released SPRINT Trial showed a significant reduction in cardiac events with more aggressive treatment (SBP <120) and it is anticipated that the new guidelines may be to treat to this lower level.

---

**a. National Committee for Quality Assurance (NCQA).** HEDIS 2015: Healthcare Effectiveness Data and Information Set: The percentage of members 18-85 years of age who had a diagnosis of hypertension (HTN) and whose BP was adequately controlled during the measurement year using the following criteria: Members 18–59 years of age whose BP was <140/90 mm Hg; Members 60–85 years of age without a diagnosis of diabetes whose BP was <150/90 mm Hg. (HEDIS measure also used for Medicare Star Ratings.)

**b. If hypertensive patient is already controlled in lower achieved SBP (e.g.,<140 mm Hg), treatment does not need to be adjusted.**

Guidelines are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines should be followed in most cases, but there is an understanding that, depending on the patient, the setting, the circumstances, or other factors, care can and should be tailored to fit individual needs.

Approved Jan 2016. Next scheduled review by Jan 2018
Monroe County Medical Society Community-wide Guidelines

Prevention, Diagnosis and Management of Coronary Artery Disease

High Risk Populations/Disparities

- Cancer and heart disease are the leading causes of premature death (average years of potential life lost before age 75 (YPLL) in Monroe County from 2006 to 2010. County-wide, the average YPLL is 6.7 years. The average YPLL is two times higher in the city compared to the suburbs and more than 3 times higher among African American and Latino residents compared to White residents.\(^1\)
- Two conditions that are risk factors for heart disease include diabetes and high blood pressure. Ten percent (10%) of Monroe County adults have diabetes, and 32% have high blood pressure.\(^1\)

<table>
<thead>
<tr>
<th>Ever Told by a Doctor or Health Professional that they have Diabetes or High Blood Pressure, Adults Ages 35+, 2012 (% of population)</th>
<th>City</th>
<th>Suburbs</th>
<th>African American</th>
<th>Latino</th>
<th>White</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>19*</td>
<td>12</td>
<td>24**</td>
<td>19**</td>
<td>12</td>
</tr>
<tr>
<td>High Blood Pressure</td>
<td>50*</td>
<td>39</td>
<td>64**</td>
<td>42</td>
<td>39</td>
</tr>
</tbody>
</table>

\(^*\) Statistical significance \(p<0.05\), City compared to Suburbs, \(^**\) Statistical significance \(p<0.05\) African American and Latino compared to White.

Quality Measures Commonly Used by National Organizations

- Antiplatelet Therapy: Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who were prescribed aspirin or clopidogrel for aspirin intolerant patients. \((PQRS)\)
- Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%): Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have prior MI OR a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed beta-blocker therapy. \((PQRS, Meaningful Use)\)
- Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy: Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%) - Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have diabetes OR a current or prior Left Ventricular Ejection Fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy. \((PQRS)\)
- Symptom Management: Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period with an evaluation of level of activity and an assessment of whether anginal symptoms are present or absent with appropriate management of anginal symptoms within a 12 month period. \((PQRS)\)

a. National Committee for Quality Assurance (NCQA). HEDIS 2015: Healthcare Effectiveness Data and Information Set: The percentage of members 18-85 years of age who had a diagnosis of hypertension (HTN) and whose BP was adequately controlled during the measurement year using the following criteria: Members 18–59 years of age whose BP was \(<140/90\) mm Hg; Members 60–85 years of age without a diagnosis of diabetes whose BP was \(<150/90\) mm Hg. (HEDIS measure also used for Medicare Star Ratings.)
b. If hypertensive patient is already controlled in lower achieved SBP (e.g., \(<140\) mm Hg), treatment does not need to be adjusted.

Guidelines are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines should be followed in most cases, but there is an understanding that, depending on the patient, the setting, the circumstances, or other factors, care can and should be tailored to fit individual needs.

Approved Jan 2016. Next scheduled review by Jan 2018
Prevention and Diagnosis

### Initial Assessment of Risk Factors - Beginning at Age 20 to Include

- Family History
- Smoking Status and Readiness to Change
- Blood Pressure
- Fasting Lipid Panel
- Dietary and Physical Activity Assessment
- BMI Calculation
- Past Medical History Assessment (including history of atrial fibrillation and diabetes)
- Waist Circumference

### Clinical Identification of Metabolic Syndrome – Any 3 of the Following:

- Waist Circumference $\geq 40''$ (men), $\geq 35''$ (women)
- Blood Pressure $\geq 130/\geq 85$ mm/Hg
- Fasting Glucose $\geq 100$ mg/dL
- Triglycerides $\geq 150$ mg/dL
- HDL Cholesterol $< 40$ mg/dL (men), $< 50$ mg/dL (women)

**Assess and treat underlying causes**

### Blood Pressure

- Treat to blood pressure target levels: $< 140/90$ mm Hg for ages $< 60$ and $< 150/90$ mm Hg for ages $\geq 60$ with no diabetes and no kidney disease$^{1,2}$
- Prescribe lifestyle modifications (e.g. effectiveness of regular aerobic exercise, moderation of sodium intake, a DASH eating plan or a Mediterranean style diet with emphasis on eating foods like fish, fruits, vegetables, beans, high-fiber breads and whole grains, nuts, and olive oil while limiting meats, cheeses, and sweets. This can be equivalent to drug monotherapy).
- Initial antihypertensive treatment:
  - In general nonblack population, including those with diabetes, initial antihypertensive treatment should include a thiazide-type diuretic, calcium channel blocker (CCB), angiotensin-converting enzyme inhibitor (ACEI), or angiotensin receptor (ARB).
  - In the general black population, including those with diabetes, initial antihypertensive treatment should include a thiazide-type diuretic or CCB.$^3$
  - In the population aged $\geq 18$ years with CKD (including all CKD patients with hypertension regardless of race or diabetes status), initial (or add-on) antihypertensive treatment should include an ACEI orARB to improve kidney outcomes.

(See Monroe County Medical Society (MCMS) *Community-wide Guideline for Management of Hypertension* for complete recommendations.)

---

**Footnotes:**

1. National Committee for Quality Assurance (NCQA). HEDIS 2015: Healthcare Effectiveness Data and Information Set: The percentage of members 18-85 years of age who had a diagnosis of hypertension (HTN) and whose BP was adequately controlled during the measurement year using the following criteria: Members 18–59 years of age whose BP was $< 140/90$ mm Hg; Members 60–85 years of age without a diagnosis of diabetes whose BP was $< 150/90$ mm Hg. (HEDIS measure also used for Medicare Star Ratings.).
2. If hypertensive patient is already controlled in lower achieved SBP (e.g., $< 140$ mm Hg), treatment does not need to be adjusted.
3. 2014 ADA Standard of Medical Care: Pharmacological therapy for patients with diabetes and hypertension should comprise a regimen that includes either an ACE inhibitor or an angiotensin receptor blocker (ARB). If one class is not tolerated, the other should be substituted.

Guidelines are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines should be followed in most cases, but there is an understanding that, depending on the patient, the setting, the circumstances, or other factors, care can and should be tailored to fit individual needs.
Diagnosis of Patients with Suspected Coronary Artery Disease*

- Suspected Coronary Artery Disease (or change in clinical status in a patient with known CAD)
  - Intermediate or high-risk UA/NSTEMI Guideline
  - Comprehensive clinical assessment of risk, including personal characteristics, coexisting cardiac and medical conditions, and health status
  - Symptoms or findings suggest high-risk lesion(s) (2)
  - OR Prior aborted sudden cardiac death or serious ventricular arrhythmia OR Prior stent in unprotected left main coronary artery

- Recent exercise or cardiac imaging study
  - Patient able to exercise
  - Low likelihood CAD
  - Intermediate to high likelihood CAD
    - MI or Echo with exercise
    - CCTA
  - Previous coronary revascularization
  - Test results suggest high-risk coronary lesion(s)

- Initiate Guideline-Directed Medical Therapy (See 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis & Mgmt of Patients with Stable Ischemic Heart Disease, Figure 5) (3)

- Consider coronary revascularization to improve symptoms
  - OR
  - Successful Treatment
  - Regular Monitoring

- Contraindications to stress testing
  - Patient unable to exercise
  - Low likelihood CAD
  - Intermediate to high likelihood CAD
    - MI or Echo with exercise or pharmacological
    - CCTA

- Initiate Guideline-Directed Therapy: consider coronary revascularization to improve survival

(1) See Table 2 in 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease for short-term risk of death or nonfatal MI in patients with UA/NSTEMI. (2) 2012 ACCF/AHA Focused Update: Guideline for the Mgmt of Patients With UA/NSTEMI. (3) CCTA is reasonable only for patients with intermediate probability of CAD. (4) 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease

CCTA: computed coronary tomography angiography; CMR: cardiac magnetic resonance; ECG: electrocardiogram; Echo: echocardiography; IHD: Ischemic Heart Disease; MI: myocardial infarction; MPI: myocardial perfusion imaging; Pharm: pharmacological; UA: unstable angina; UA/NSTEMI: unstable angina/non-ST-segment elevation myocardial infarction


Guidelines are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines should be followed in most cases, but there is an understanding that, depending on the patient, the setting, the circumstances, or other factors, care can and should be tailored to fit individual needs.
Diagnosis, Prevention and Management of Coronary Artery Disease

**Lipid Management***

<table>
<thead>
<tr>
<th>Statin Benefit Patient Groups(1)</th>
<th>Recommended Statin Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical ASCVD(2) - secondary prevention</strong></td>
<td>Age ≤75 yrs with no statin-related safety concerns</td>
</tr>
<tr>
<td></td>
<td>Age &gt;75 yrs or not a candidate for high-intensity statins</td>
</tr>
<tr>
<td><strong>Individuals with primary elevations of LDL-C ≥190 mg/dL and without clinical ASCVD - primary prevention</strong></td>
<td>Familial hypercholesterolemia (candidates for statin therapy)</td>
</tr>
<tr>
<td><strong>Individuals with diabetes, ages 40-75, with LDL-C 70-189 mg/dL and without clinical ASCVD - primary prevention</strong></td>
<td>Estimated 10-yr ASCVD risk &lt;7.5%</td>
</tr>
<tr>
<td></td>
<td>Estimated 10-yr ASCVD risk ≥7.5%</td>
</tr>
<tr>
<td><strong>Individuals with no diabetes, ages 40-75, with LDL-C 70-189 mg/dL and without clinical ASCVD - primary prevention</strong></td>
<td>Estimated 10-yr ASCVD risk ≥7.5%</td>
</tr>
<tr>
<td></td>
<td>Estimated 10-yr ASCVD risk 5 – &lt; 7.5%</td>
</tr>
</tbody>
</table>

For patients who do not fall into the above statin-benefit groups, physicians and patients should engage in a discussion regarding the risks and benefits of therapy. Clarification of the role and appropriate use of new inhibitors is pending.

Consider pill splitting or generic equivalents as available to increase patient compliance.

---

**Risk Intervention**

**Lifestyle Modifications**

- Physical activity of at least 150 min/wk of moderate-intensity aerobic activity over at least 5 days/wk or 75 min/wk of vigorous-intensity aerobic activity over at least 3 days/wk and muscle-strengthening activities on 2 or more days/wk that work all major muscle groups.
- Dietary Intake: moderation of sodium intake, a DASH eating plan or a Mediterranean style diet with emphasis on eating foods like fish, fruits, vegetables, beans, whole grains, nuts, and olive oil while limiting meats, cheeses, and sweets.
- Weight Management to achieve and maintain BMI at 18.5 – 24.9 Kg/m², waist circumference at iliac crest level ≤ 40” in men & ≤ 35” in women.
- Complete smoking cessation. Provide appropriate counseling, pharmacotherapy and referral to formal cessation programs. No exposure to environmental smoke. (See MCMC Community-wide Guideline for Treating Tobacco Use and Dependence).

**Blood Lipid Management**

Initiate therapeutic lifestyle changes and consider drug therapy.

**Diabetes Management**

Initiate appropriate therapy to achieve an A1c < 7.0% (Goals should be individualized based on age, comorbidity conditions, duration of diabetes, individual patient considerations and other factors.) (See MCMS Community-wide Guideline for Diabetes Care)

**ASA Therapy**

- Primary Prevention - The Food and Drug Administration does not recommend aspirin therapy as preventive medicine in people who have not already had a heart attack, stroke or other cardiovascular conditions. As of 2015 the United States Preventive Services Task Force updated its recommendation for Aspirin for the Prevention of Cardiovascular Disease - Primary Prevention
- Secondary Prevention - 2 or more risk factors, especially those with CHD 10yr risk of >10%, and no contraindications– prescribe 81-162 mg/QD.

**Depression Screening**

Screen for depression (See MCMS Community-wide Guideline for Major Depressive Disorder)

**Disease Management Support**

- One to one interaction for personal education and support.
- Resource tools to assist with self management of chronic conditions

---


1. Characteristics that may predispose patients to statin adverse effects include, but are not limited to: multiple or serious comorbidities, including impaired renal, hepatic function; hx of previous statin intolerance or muscle disorders; unexplained ALT elevations >3 X ULN; age >75 yrs. 2. Atherosclerotic Cardiovascular Disease (ASCVD) defined as acute coronary syndrome, history of myocardial infarction, stable or unstable angina, prior coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be atherosclerotic.

Guidelines are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines should be followed in most cases, but there is an understanding that, depending on the patient, the setting, the circumstances, or other factors, care can and should be tailored to fit individual needs.

Monroe County Medical Society Community-wide Guidelines

Diagnosis, Prevention and Management of Coronary Artery Disease

Patient Tracking Tool for Secondary CVD

<table>
<thead>
<tr>
<th>RISK INTERVENTIONS</th>
<th>INITIAL STATUS</th>
<th>PATIENT GOAL</th>
<th>DATE:</th>
<th>DATE:</th>
<th>DATE:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking</td>
<td>Smoker</td>
<td>Smoker</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete avoidance/</td>
<td>Non-smoker</td>
<td>Non-smoker</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cessation including ENDS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood Pressure</td>
<td>mmHg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 140/90 mm Hg for ages &lt; 60</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 150/90 mm Hg for ages ≥ 60</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>with no diabetes &amp; no kidney disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholesterol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial screening w/lipid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>panel/therapy based on risk</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>calculation (Screen for familial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>lipdemia to identify higher risk individuals)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical Activity</td>
<td>Duration</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>150 min/wk (moderate over at</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>least 5 days) or 75 min/wk</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(vigorous over at least 3 days) plus muscle strengthening (2 or more days/wk)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight Mgmt.</td>
<td>Height</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI: &lt; 25</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waist Circumference</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men &lt; 40“</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women &lt; 35”</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes Management*</td>
<td>HbA1c</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HbA1c &lt; 7.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiplatelet Agents/Anticoagulants**</td>
<td>Yes/No</td>
<td>Compliant?</td>
<td>Y/N</td>
<td>Y/N</td>
<td>Y/N</td>
</tr>
<tr>
<td></td>
<td>Rx</td>
<td>Rx</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ace Inhibitors</td>
<td>Yes/No</td>
<td>Compliant?</td>
<td>Y/N</td>
<td>Y/N</td>
<td>Y/N</td>
</tr>
<tr>
<td></td>
<td>Rx</td>
<td>Rx</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>Yes/No</td>
<td>Compliant?</td>
<td>Y/N</td>
<td>Y/N</td>
<td>Y/N</td>
</tr>
<tr>
<td></td>
<td>Rx</td>
<td>Rx</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression Screening</td>
<td>Yes/No</td>
<td>Y/N</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Goals should be individualized based on age/life expectancy, duration of diabetes, comorbid conditions, individual patient considerations and other factors.
**Consider annual reassessment of the need for antiplatelet/anticoagulant therapy.

METABOLIC SYNDROME INCLUDES ANY 3 OF THE 5 DIAGNOSTIC MEASURES: Waist Circumference (men ≥40", women ≥35’’); BP ≥130/85 mm Hg; FBG ≥100 mg/dL; Triglycerides ≥150 mg/dL; HDL cholesteral (men < 40 mg/dL, women < 50 mg/dL)

Guidelines are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines should be followed in most cases, but there is an understanding that, depending on the patient, the setting, the circumstances, or other factors, care can and should be tailored to fit individual needs.

Resources for Physicians

**American Heart Association** (The American Heart Association is a national voluntary health agency to help reduce disability and death from cardiovascular diseases and stroke.)
Provides featured science news, research, cardiovascular risk calculator and daily e-newsletter.

**Centers for Disease Control**

Resources for Patients

**American Heart Association**
(The American Heart Association is a national voluntary health agency to help reduce disability and death from cardiovascular diseases and stroke.)
- **Answers by Heart**: Downloadable Q & A patient information sheets, in English and Spanish, on cardiovascular conditions, tests and treatments and lifestyle and risk reduction.
- **Caregiver Resources**: online support communities, printable resources and monthly e-newsletter.

**Centers for Disease Control**
Information about physical activity for adults and older adults.

**DASH Eating Plan**
Online booklet with information about servings and food groups for the DASH eating plan; tips on switching to the DASH eating plan; lowering sodium intake, using herbs and spices, and comparing labels; and how to lose weight.

**Mediterranean Diet**
Information in English and Spanish from Medline Plus, a service of the **U.S. National Library of Medicine National Institutes of Health**.

**Million Hearts**
Information on ABCS of prevention, Practice Healthy Living Habits

**National Heart Lung & Blood Institute**
Tips for a lifelong approach to prevent and control coronary heart disease risk factors.

**USDA Choose My Plate**
- **Tips for increasing physical activity** – How to make physical activity a regular part of the day at home, work and play.
- **How much physical activity is needed?**


SPRINT Trial website: https://www.sprinttrial.org/


U.S. Food and Drug Administration. Use of Aspirin for Primary Prevention of Heart Attack and Stroke. May 2014. Available at: www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm390574.htm

Guidelines are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines should be followed in most cases, but there is an understanding that, depending on the patient, the setting, the circumstances, or other factors, care can and should be tailored to fit individual needs.